Treating anaemia in chronic kidney disease improves cardiovascular outcome by improving left ventricular mass index


  • Kavita J. Rawat Department of Medicine, Seth G. S. Medical College, Parel, Mumbai, Maharashtra, India
  • Kavita S. Joshi Department of Medicine, Seth G. S. Medical College, Parel, Mumbai, Maharashtra, India
  • Rahul D. Arora Department of Medicine, Seth G. S. Medical College, Parel, Mumbai, Maharashtra, India



Anaemia, CKD, LVH, LVMI


Background: Chronic kidney disease (CKD) has a high global prevalence of 11 to 13% with majority in stage 3.This has increased the burden on health care. Anaemia is important and independent risk factor for adverse cardiovascular outcome in CKD.

Methods: Prospective observational study conducted over one year at KEM Hospital, Mumbai a tertiary care centre. Inclusion criteria were newly diagnosed patients with CKD above 18 years and excluded pregnant women, patients previously diagnosed as CKD, Ischemic heart disease and on maintenance haemodialysis. Complete haemogram, renal function tests, liver function tests, serum albumin, serum calcium, serum phosphorus, serum parathyroid hormone level, ECG and 2DEchocardiography were recorded. It was repeated at the end of one year after correcting Hb with human recombinant erythropoietin.

Results: In all 102 patients, anaemia and left ventricular mass index (LVMI) are negatively correlated with each other at the start and end of the study with a correlation coefficient (r) of - 0.3 and 0.56 respectively. The change in haemoglobin and change in LVMI are also negatively correlated with correlation coefficient (r) of - 0.65. All the correlations are statistically significant. There was a significant improvement in haemoglobin, and there was a significant decrease in LVMI in all the patients. There was a partial regression in left ventricular hypertrophy with partial correction of anaemia in these patients.

Conclusions: Anaemia and LVH in patients with CKD are negatively correlated. Treatment of anaemia with erythropoietin has been shown to induce a partial regression of LVMI.


National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.

Hill NR, Fatoba ST, Oke JL, Hirst JA, Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. Remuzzi G, ed. PLoS ONE. 2016;11(7):e0158765.

Varma PP. Prevalence of chronic kidney disease in India - where are we heading? Indian J Nephrol. 2015;25(3):133-5.

Trivedi H, Vanikar A, Patel H, Kanodia K, Kute V, Nigam L, et al. High prevalence of chronic kidney disease in a semi-urban population of Western India. Clin Kidney J. 2016;9(3):438-43.

Abramson JL, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003;64(2):610-5.

Jurkovitz CT, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2003;14(11):2919-25.

McClellan FW, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 2002;13(7):1928-36.

Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, et al. Anemia as a risk factor for cardiovascular disease in. The atherosclerosis risk in communities (ARIC) study. J Am Coll Cardiol. 2002;40(1):27-33.

Ma EJ, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10(3):610-9.

Xia EJ, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10(6):1309-16.

Collins AJ, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12(11):2465-73.

Collins MJ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol. 2000;20(4):345-9.

Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11(7):1277-85.

Parfrey FR. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10(7):1606-15.

Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol. 2009;20(12):2651-60.

Rajapurkar MM, John GT, Kirpalani AL, Abraham G, Agarwal SK, Almeida AF, et al. What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol. 2012;13:10.

Astor BC, Brown A, Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis. 2004;43(5):836-45.

Chen SC, Chang JM, Liu WC, Tsai YC, Tsai JC, Su HM, et al. Stepwise increases in left ventricular mass index and decreases in left ventricular ejection fraction correspond with the stages of chronic kidney disease in diabetes patients. Exp Diabetes Res. 2012;2012:789325.

Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46(2):320-7.

Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27(3):347-54.

Ulasi, II, Arodiwe EB, Ijoma CK. Left ventricular hypertrophy in African Black patients with chronic renal failure at first evaluation. Ethn Dis. 2006;16(4):859-64.

Zehnder C, Zuber M, Sulzer M, Meyer B, Straumann E, Jenzer HR, et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron. 1992;61(1):21-5.

Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int. 2005;68(2):788-95.

Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000;35(2):250-6.

Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613-8.

Romhilt DW, Estes EH. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J. 1968;75(6):752-8.






Original Research Articles